119831-72-0Relevant academic research and scientific papers
Treatment of obesity
-
, (2008/06/13)
A method for the treatment of obesity in an animal such as a human, comprises administering to the animal an effective amount of a peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone, particularly an analogue of the carboxyl-terminal sequence of human growth hormone containing amino acid residues 177-191. A pharmaceutical composition for use in the treatment of obesity is also disclosed.
GLP-2 compounds, formulations, and uses thereof
-
, (2008/06/13)
The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
An acid labile arginine derivative for peptide synthesis: N(G)-2,2,5,7,8-pentamethylchroman-6-sulphonyl-L-arginine
Ramage,Green,Blake
, p. 6353 - 6370 (2007/10/02)
A trifluoroacetic acid (TFA) labile protecting group for the guanidine side chain function of arginine has been developed. N(G)-(2,2,5,7,8-Pentamethylchroman-6-sulphonyl-L-arginine is cleaved rapidly in TFA or 50% TFA in dichloromethane at room temperatur
APPLICATION OF THE NG-(2,2,5,7,8-PENTAMETHYLCHROMAN-6-SULPHONYL) DERIVATIVE OF FMOC-ARGININE TO PEPTIDE SYNTHESIS
Green, J.,Ogunjobi, O. M.,Ramage, R.,Stewart, A. S. J.
, p. 4341 - 4344 (2007/10/02)
The trifluoroacetic acid labile pentamethylchromanylsulphonyl protecting group for the guanidino group of arginine has been used in conjunction with the base-labile Fmoc Nα protecting group for the synthesis of arginine-containing peptides.
